For the blood levels to be steady, equipoise needs to be administered at least once a week. In men, the common dosage is in the range of 400-600mg while in women it is around 50-150 mg per week. Stacking with Anadrol , Diabanol , or other injectable testosterone steroids like Sustanon or Testoviron depot can contribute to mass development. This steroid is a great hit among those who are preparing for contests as it does not aromatize well at all. Combining equipoise with Winstrol or Parabolan can greatly improve muscle hardness and density.
Equipoise is most effective when stacked with other performance enhancers. It should not be used for more than 16 weeks at a stretch. Users will notice improved blood flow and better blood volume as the cycle goes on. Effects are likely to appear a few weeks after you start the cycle.
Blinding : the process of preventing one or more of patients, clinicians, investigators, and data analysts from knowing whether individual patients are receiving the investigational intervention(s) or the control (or standard) intervention(s) in a clinical trial. (Also known as masking.) Blinding is intended to eliminate the possibility that knowledge of which intervention is being received will affect patient outcomes, investigator behaviors that may affect outcomes, or assessment of outcomes. Blinding is not always practical (. when comparing surgery to drug treatment), but it should be used whenever it is possible and compatible with optimal patient care. The terms “single-blinded,” “double-blinded,” and “triple-blinded” refer to which parties are blinded, ., one or more of patients, investigators, and data analysts; however, these terms are used inconsistently and the specific parties who are blinded in a trial should be identified.
The ethics of clinical research requires equipoise--a state of genuine uncertainty on the part of the clinical investigator regarding the comparative therapeutic merits of each arm in a trial. Should the investigator discover that one treatment is of superior therapeutic merit, he or she is ethically obliged to offer that treatment. The current understanding of this requirement, which entails that the investigator have no "treatment preference" throughout the course of the trial, presents nearly insuperable obstacles to the ethical commencement or completion of a controlled trial and may also contribute to the termination of trials because of the failure to enroll enough patients. I suggest an alternative concept of equipoise, which would be based on present or imminent controversy in the clinical community over the preferred treatment. According to this concept of "clinical equipoise," the requirement is satisfied if there is genuine uncertainty within the expert medical community--not necessarily on the part of the individual investigator--about the preferred treatment.